State Street Corp Increases Stock Position in Pfizer Inc. $PFE

State Street Corp raised its stake in Pfizer Inc. (NYSE:PFE) by 1.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 307,090,897 shares of the biopharmaceutical company’s stock after purchasing an additional 5,501,032 shares during the quarter. State Street Corp owned 0.05% of Pfizer worth $7,394,749,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Security National Bank of Sioux City Iowa IA purchased a new position in shares of Pfizer in the second quarter valued at $76,000. Bullseye Investment Management LLC acquired a new stake in Pfizer in the 2nd quarter worth about $28,000. U S Wealth Group LLC. grew its holdings in Pfizer by 13.1% in the second quarter. U S Wealth Group LLC. now owns 116,761 shares of the biopharmaceutical company’s stock valued at $2,812,000 after purchasing an additional 13,516 shares during the period. Core Capital Management & Research inc. purchased a new stake in shares of Pfizer during the 2nd quarter valued at $4,687,000. Finally, Community Bank of Raymore increased its stake in Pfizer by 33.8% during the second quarter. Community Bank of Raymore now owns 60,520 shares of the biopharmaceutical company’s stock worth $1,457,000 after acquiring an additional 15,300 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have commented on PFE shares. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Bank of America cut their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. UBS Group reiterated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Wednesday, May 27th. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Sunday, September 13th. Finally, HSBC raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $28.39.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Management’s message that tariffs, drug-pricing pressures, declining COVID-19 revenue and upcoming patent expirations are becoming more manageable is supporting the recovery narrative. Cost-cutting efforts and a larger contribution from newer therapies could help offset declining legacy-product sales. Pfizer’s agreement to share some additional overseas pricing revenue with the U.S. Department of Health and Human Services may also reduce regulatory uncertainty. How Investors Are Reacting To Pfizer Easing Policy Pressures And New HHS Revenue-Sharing Deal
• Positive Sentiment: Pfizer completed a key Phase 1 study for PF-07799544, advancing the experimental drug into the next stage of development. Although early-stage data do not establish commercial success, continued pipeline progress could improve confidence in Pfizer’s post-patent-expiry growth prospects. Pfizer Advances PF-07799544 With Completion of Key Phase 1 Study
• Positive Sentiment: Several investment commentaries argue that Pfizer’s valuation and dividend yield already reflect substantial pessimism, leaving room for a potential re-rating if earnings stabilize after major loss-of-exclusivity events. The roughly 6% yield remains attractive to income-oriented investors. Pfizer: A Conservative Valuation Leaves Room For A Post-LOE Re-Rating
• Neutral Sentiment: CEO Albert Bourla reportedly plans to attend the White House state dinner for Chinese President Xi Jinping. The appearance could support visibility around U.S.-China pharmaceutical relations, but it has no immediate, clearly measurable earnings impact. Pfizer CEO Bourla plans to attend White House state dinner for China’s Xi
• Negative Sentiment: More cautious analysis says investors may not pay for Pfizer’s 2029 earnings potential until the company demonstrates durable growth, while dividend increases appear limited. Patent expirations, weak COVID-related sales and execution risk continue to constrain the stock’s upside. Pfizer: The Market Won’t Pay For 2029 Until It Can

Pfizer Stock Performance

NYSE:PFE traded up $0.09 during midday trading on Tuesday, reaching $27.83. 11,582,337 shares of the company traded hands, compared to its average volume of 41,026,941. Pfizer Inc. has a twelve month low of $23.58 and a twelve month high of $29.21. The firm has a market capitalization of $158.61 billion, a price-to-earnings ratio of 36.63, a price-to-earnings-growth ratio of 1.86 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The company has a fifty day moving average price of $26.77 and a 200 day moving average price of $26.38.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the company earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.2%. The ex-dividend date of this dividend was Friday, July 24th. Pfizer’s payout ratio is presently 226.32%.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer’s products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.